IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Other languages
English (en)
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (cg-RX-API-DMAC7.html) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (cg-RX-API-DMAC7.html) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (cg-RX-API-DMAC7.html)
EP (1) EP2808018B1 (cg-RX-API-DMAC7.html)
JP (1) JP5924699B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140134266A (cg-RX-API-DMAC7.html)
CN (1) CN104066430A (cg-RX-API-DMAC7.html)
AR (1) AR089812A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013212865A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014017902A2 (cg-RX-API-DMAC7.html)
CA (1) CA2862602A1 (cg-RX-API-DMAC7.html)
HK (1) HK1201209A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN05972A (cg-RX-API-DMAC7.html)
MX (1) MX2014008484A (cg-RX-API-DMAC7.html)
RU (1) RU2014134845A (cg-RX-API-DMAC7.html)
TW (1) TW201334779A (cg-RX-API-DMAC7.html)
WO (1) WO2013111870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP2009501795A (ja) * 2005-07-21 2009-01-22 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
JP5242393B2 (ja) 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド 高血圧症の治療方法
EP1957064A4 (en) * 2005-11-21 2010-01-06 Tap Pharmaceutical Prod Inc TREATMENT OF QT INTERVAL EXTENSION AND RELEVANT DISEASES
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ii型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
JP2010509372A (ja) 2006-11-13 2010-03-25 タケダ・フアーマシユーテイカルズ・ノース・アメリカ・インコーポレイテツド キサンチン酸化還元酵素阻害剤を使用する腎機能保持方法
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
CN102015726B (zh) * 2008-03-31 2014-07-23 C&C新药研究所 杂环衍生物
CA2722624C (en) * 2008-04-30 2017-03-21 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
US8791077B2 (en) * 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
EP2398319A4 (en) * 2008-10-19 2012-11-14 Richard J Johnson THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHRONIC NEPHITIA ASSOCIATED WITH METABOLIC IMBALANCE
EP2470268A4 (en) * 2009-08-24 2012-12-26 Wound Man Pty Ltd PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS
JP5865904B2 (ja) * 2010-06-16 2016-02-17 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド キサンチンオキシドレダクターゼ阻害剤またはキサンチンオキシダーゼ阻害剤の新規の調節放出剤形
KR20130088755A (ko) * 2010-06-25 2013-08-08 데이진 화-마 가부시키가이샤 서방성 고혈압 및 신 기능 장애 치료제

Also Published As

Publication number Publication date
EP2808018A1 (en) 2014-12-03
BR112014017902A2 (pt) 2017-08-22
RU2014134845A (ru) 2016-03-20
CN104066430A (zh) 2014-09-24
AR089812A1 (es) 2014-09-17
JPWO2013111870A1 (ja) 2015-05-11
AU2013212865A1 (en) 2014-08-14
HK1201209A1 (en) 2015-08-28
EP2808018B1 (en) 2018-03-14
WO2013111870A1 (ja) 2013-08-01
CA2862602A1 (en) 2013-08-01
JP5924699B2 (ja) 2016-05-25
KR20140134266A (ko) 2014-11-21
TW201334779A (zh) 2013-09-01
US20150005506A1 (en) 2015-01-01
MX2014008484A (es) 2014-10-14
EP2808018A4 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
IN2015MN00404A (cg-RX-API-DMAC7.html)
MY183312A (en) Pharmaceutical formulation
AU2012214029A8 (en) Rorgammat inhibitors
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015502839B1 (en) Antiviral compounds
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12017501426A1 (en) Derivatives of betulin
IN2015DN00185A (cg-RX-API-DMAC7.html)
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
MX2015010971A (es) Derivado novedoso de pirazol.
IN2014MN02106A (cg-RX-API-DMAC7.html)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
IN2014DN05972A (cg-RX-API-DMAC7.html)
MY187718A (en) Pharmaceutical formulations
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX390763B (es) Compuestos de tetraciclina
WO2011159124A3 (ko) Interleukin-6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2011123536A8 (en) Polycyclic tetracycline compounds
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (cg-RX-API-DMAC7.html)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids